Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dengue virus-1 antigens refers collectively to the proteins expressed by the Dengue virus serotype 1 (DENV-1) that are recognized by the immune system. Key antigens include the envelope (E) protein, which mediates viral entry and serves as the primary target for neutralizing antibodies; the capsid (C) protein, essential for genome encapsidation; the non-structural proteins (particularly NS1, NS3, and NS5), which are involved in viral replication and immune modulation; and the membrane (M/prM) protein, which is important for virion maturation. The E and NS1 proteins are utilized in diagnostics and are major therapeutic or vaccine targets. However, "Dengue virus-1 antigens" is a broad term and not a specific molecular target; for structured pharmacological purposes, referencing a specific DENV-1 protein is necessary[1][3][4][6].
Inhibition of viral entry (E protein inhibitors and neutralizing antibodies); Inhibition of viral assembly/capsid formation (capsid inhibitors); Blockage of NS1-mediated immune modulation and vascular leakage (NS1 inhibitors/antibodies)
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue virus-1 antigens (DEN-1 E protein).